Medtronic Sees Unusually Large Options Volume (NYSE:MDT)

Medtronic PLC (NYSE:MDT) saw unusually large options trading activity on Tuesday. Traders acquired 33,681 call options on the company. This is an increase of 140% compared to the typical daily volume of 14,053 call options.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDT. California State Teachers Retirement System boosted its holdings in Medtronic by 7,655.7% in the second quarter. California State Teachers Retirement System now owns 158,124,578 shares of the medical technology company’s stock worth $12,370,086,000 after acquiring an additional 156,085,748 shares in the last quarter. BlackRock Inc. raised its position in shares of Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after purchasing an additional 838,220 shares during the last quarter. State Street Corp raised its position in shares of Medtronic by 2.0% in the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after purchasing an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Medtronic by 2.7% in the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after purchasing an additional 1,419,730 shares in the last quarter. Finally, Capital Research Global Investors boosted its stake in Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after purchasing an additional 3,880,174 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MDT has been the subject of several research analyst reports. Sanford C. Bernstein decreased their target price on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Wells Fargo & Company decreased their price objective on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, June 4th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a report on Thursday, June 4th. Finally, The Goldman Sachs Group dropped their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.79.

Medtronic Stock Up 2.0%

Shares of MDT traded up $1.78 during trading hours on Tuesday, hitting $92.43. The company had a trading volume of 10,169,695 shares, compared to its average volume of 8,852,474. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $118.30 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic has a one year low of $73.31 and a one year high of $106.33. The company’s fifty day moving average price is $85.81 and its two-hundred day moving average price is $85.48.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts forecast that Medtronic will post 5.94 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is 77.21%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported adjusted earnings of $1.45 per share, above the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, exceeding expectations of approximately $9.55 billion. Growth was broad-based across cardiovascular, neuroscience, medical surgical and diabetes businesses. Medtronic Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Cardiovascular revenue climbed 19.5% on reported growth, supported by demand for devices used in complex procedures. Neuroscience, medical surgical and diabetes revenue also grew at double-digit rates, reinforcing the company’s growth outlook. Medtronic boosts fiscal 2027 forecasts on heart device demand
• Positive Sentiment: Management raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75% and set adjusted EPS guidance at $5.94-$6.00, citing improved margins, portfolio strength and newer growth platforms. Medtronic reports first quarter fiscal 2027 results
• Positive Sentiment: Medtronic committed approximately $700 million to a partnership with Cornerstone Robotics, gaining distribution rights for the Sentire surgical system in select markets outside the U.S. The company also agreed to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic valve replacement procedures. These moves broaden its robotics and structural-heart offerings. Medtronic Announces Strategic Partnership with Cornerstone Robotics
• Positive Sentiment: Unusually heavy call-option activity and generally favorable analyst opinions, along with Medtronic’s dividend yield above 3%, added to the constructive investor sentiment.
• Neutral Sentiment: The stock showed relative strength even as broader U.S. markets traded lower, suggesting the earnings beat and raised outlook were outweighing broader risk-off conditions.
• Negative Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus estimate, and the sizeable robotics investment could increase near-term execution and integration risks.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).